Beranda › Kanker Endometrium › Rhode Island
Uji klinis Kanker Endometrium di Rhode Island
14 studi untuk Kanker Endometrium mencari peserta di lokasi di Rhode Island.
Kota di Rhode Island
Teks studi resmi (Bahasa Inggris)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Women and Infants Hospital, Providence
- Roger Williams Medical Center, Providence
Menerima pesertaFase 2
Semua usia · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05564377Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- Women and Infants Hospital, Providence
Menerima pesertaFase 1
Usia 18 ke atas · Wanita · Diperbarui 2 Okt 2026 · NCT05950464Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Rhode Island Hospital, Providence
- Women and Infants Hospital, Providence
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 2 Okt 2026 · NCT07198074Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Women and Infants Hospital, Providence
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 28 Sep 2026 · NCT05112601Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Women and Infants Hospital, Providence
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 24 Sep 2026 · NCT05640999A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Women & Infants Hospital ( Site 5003), Providence
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 17 Sep 2026 · NCT06952504A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Women & Infants Hospital of Rhode Island, Providence
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06515613DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Providence
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 3 Sep 2026 · NCT06989112Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Providence
Menerima pesertaFase 1/2
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT05797168A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Women & Infants Hospital, Providence
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 21 Agu 2026 · NCT05548296Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Women and Infants Hospital of Rhode Island, Providence
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT05579366Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Women & Infants Hospital, Providence
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Nov 2025 · NCT05997017A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Women & Infants Hospital, Providence
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Nov 2025 · NCT05902988SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Providence
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.